Yossi Gilgun‐Sherki

Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease1This manuscript is based on a poster presented at the Brain Research Interactive Symposium on “Neuropeptides at the Millennium”, Miami, October 1999.1

Daniel Offen, Yossi Gilgun‐Sherki, Eldad Melamed et al. · Brain Research · 2000 · 141 citations

Neurodegenerative Diseases, Neuropeptides, Neurobiology Of Disease +15

A low molecular weight copper chelator crosses the blood–brain barrier and attenuates experimental autoimmune encephalomyelitis

Daniel Offen, Yossi Gilgun‐Sherki, Yael Barhum et al. · Journal of Neurochemistry · 2004 · 133 citations · Full text

Immunology, Immune Regulation, Innate Immunity +26

Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis

Yossi Gilgun‐Sherki, Hana Panet, Eldad Melamed et al. · Brain Research · 2003 · 106 citations

Autoimmune Disease, Neurological Disorder, Medicine +9

Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis

Yossi Gilgun‐Sherki, Hana Panet, Vered Holdengreber et al. · Neuroscience Research · 2003 · 75 citations

Inflammation, Glatiramer Acetate Treatment, C57/bl Mice +9

A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease

Merav Bahat‐Stroomza, Yossi Gilgun‐Sherki, Daniel Offen et al. · European Journal of Neuroscience · 2005 · 71 citations